BostickGKamperSHaanstraT, et al. (2017) Pain expectations in neuropathic pain: is it best to be optimistic?European Journal of Pain21(4): 605–613. DOI: 10.1002/ejp.962.
3.
BouhassiraDAttalNAlchaarH, et al. (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain114(1–2): 29–36. DOI: 10.1016/j.pain.2004.12.010.
4.
ChoiDGoodwinGStevensEB, et al. (2023) Spontaneous activity in peripheral sensory nerves: a systematic review. Pain165(5): 983–996. DOI: 10.1097/j.pain.0000000000003115.
5.
ChopraKTiwariV (2012) Alcoholic neuropathy: possible mechanisms and future treatment possibilities. British Journal of Clinical Pharmacology73(3): 348–362. DOI: 10.1111/j.1365-2125.2011.04111.x.
6.
ClauwDJ (2014) Fibromyalgia: a clinical review. JAMA311(15): 1547–1555. DOI: 10.1001/jama.2014.3266.
De SouzaJMTrevisanTJSepresseSR, et al. (2023) Peripheral neuropathy in systemic autoimmune rheumatic diseases – diagnosis and treatment. International Journal of Molecular Sciences24(9): 7835. DOI: 10.3390/ijms24097835.
9.
DourmapLSallesN (2015) Peripheral neuropathy in HIV: Drug-induced neuropathies. Journal of Antimicrobial Chemotherapy70(6): 1624–1631. DOI: 10.1093/jac/dkv035.
10.
DydykAMGivlerA (2023) Central pain syndrome. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available at: www.ncbi.nlm.nih.gov/books/NBK553027/ (accessed 8 April 2025).
11.
EvansEBNEvansMRB (2021) Nangs, balloons and crackers: recreational nitrous oxide neurotoxicity. Australian Journal of General Practice50(11): 834–838. DOI: 10.31128/AJGP-10-20-5668.
12.
FinnerupNBSindrupSHJensenTS (2007) Chronic neuropathic pain: Mechanisms, drug targets and measurement. Fundamental and Clinical Pharmacology21(2): 129–136. DOI: 10.1111/j.1472-8206.2007.00469.x.
13.
HamdanAGalvezRKatatiMJ (2024) Shedding light on neuropathic pain: current and emerging tools for diagnosis, screening, and quantification. SAGE Open Medicine12: 20503121231218985. DOI: 10.1177/20503121231218985.
14.
HigginsDMHeapyAAButaE, et al. (2022) A randomized controlled trial of cognitive behavioral therapy compared with diabetes education for diabetic peripheral neuropathic pain. Journal of Health Psychology27(3): 649–662. DOI: 10.1177/1359105320962262.
15.
NICE (2013) Neuropathic pain in adults: pharmacological management in non-specialist settings. Updated 22 September 2020. Available at: www.nice.org.uk/guidance/cg173 (accessed 3 March 2025).
16.
NICE (2019) Suspected neurological conditions: recognition and referral. Available at: www.nice.org.uk/guidance/ng127/ (accessed 8 April 2025).
17.
NICE (2020) Neuropathic pain in adults: pharmacological management in non-specialist settings. Available at: www.nice.org.uk/guidance/cg173/ (accessed 8 April 2025).
RogDJNurmikkoTJFriedeT, et al. (2007) Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis. The Clinical Journal of Pain23(6): 473–481. DOI: 10.1097/AJP.0b013e31805d0c5d.
21.
ThiemeKTurkDCFlorH (2004) Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosomatic Medicine66(6): 837–844. DOI: 10.1097/01.psy.0000146329.63158.40.
WalkerSLWatersMFRLockwoodDNJ (2007) The role of thalidomide in the management of erythema nodosum leprosum. Leprosy Review78(3): 197–215.
24.
WoolfCJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain152(3 Suppl.): S2–S15. DOI: 10.1016/j.pain.2010.09.030.
25.
YucelASenocakMKocasoy OrhanE, et al. (2004) Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. The Journal of Pain5(8): 427–432. DOI: 10.1016/j.jpain.2004.07.001.
26.
YunusMB (2007) Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Seminars in Arthritis and Rheumatism36(6): 339–356. DOI: 10.1016/j.semarthrit.2006.12.009.
